导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.26% | 3100/4773 |
| 近一周 | -2.61% | 2671/5462 |
| 近一月 | -7.02% | 3708/5421 |
| 近一季 | 8.47% | 178/5209 |
| 近半年 | -1.68% | 1660/4920 |
| 近一年 | -15.69% | 3713/4366 |
| 近两年 | 17.73% | 2695/2954 |
| 近三年 | -10.13% | 2033/2253 |
| 成立以来 | 0.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.99% 2605/4961 |
-5.51% 3587/5312 |
- - |
- - |
| 2025 | 5.91% 2982/4813 |
1.61% 1584/3635 |
2.24% 1719/4076 |
15.92% 2757/4524 |
-12.06% 4238/4813 |
| 2024 | -12.28% 2370/3463 |
-10.42% 2338/2808 |
-8.24% 2194/3014 |
17.18% 1250/3129 |
-8.93% 2890/3463 |
| 2023 | -10.95% 1354/2656 |
1.36% 1584/2280 |
-8.25% 1977/2385 |
-2.16% 631/2515 |
-2.13% 432/2655 |
| 2022 | -19.52% 860/2207 |
-11.19% 486/1919 |
-1.82% 1754/2016 |
-15.62% 1321/2113 |
9.39% 225/2208 |
| 2021 | -6.00% 990/1822 |
-3.75% 824/1255 |
13.62% 281/1330 |
-12.96% 1324/1466 |
-1.23% 1337/1822 |
| 2020 | 48.57% 182/1250 |
7.26% 36/1028 |
28.49% 101/1067 |
3.25% 990/1164 |
4.40% 843/1184 |
| 2019 | 32.77% 442/1092 |
27.64% 339/739 |
-6.81% 521/788 |
6.48% 125/850 |
4.82% 775/918 |
| 2018 | -24.13% 319/834 |
- - |
-1.83% 58/631 |
-13.16% 633/660 |
-16.17% 632/682 |
| 2017 | 6.28% 335/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发医药卫生联接C VS. 长安沪深300非周期A(740101) |